首页> 外文期刊>Bone marrow transplantation >Recombinant human granulocyte colony-stimulating factor (rh-G-CSF) may accelerate hematopoietic recovery after HLA-identical sibling allogeneic peripheral blood stem cell transplantation.
【24h】

Recombinant human granulocyte colony-stimulating factor (rh-G-CSF) may accelerate hematopoietic recovery after HLA-identical sibling allogeneic peripheral blood stem cell transplantation.

机译:重组人粒细胞集落刺激因子(rh-G-CSF)可以在同种异体同种异体外周血干细胞移植后加速造血恢复。

获取原文
获取原文并翻译 | 示例
       

摘要

We studied the effects of recombinant human granulocyte colony-stimulating factor (G-CSF) on hematopoietic recovery and clinical outcome in patients undergoing allogeneic peripheral blood stem cell (PBSC) transplantation. Fifty-six patients with hematological malignancies who underwent allogeneic PBSC transplantation between 1995 and 1998 were entered into this study. Twenty-eight patients who received daily G-CSF from day +1 after allogeneic PBSC transplantation until the absolute neutrophil count (ANC) reached >0.5 x 10(9)/l for 3 consecutive days were compared with 28 patients (control group) who did not receive G-CSF in a non-randomized manner. The study group and the control group were comparable with respect to baseline patient and transplantation characteristics. Median times to ANC of >0.5 x 10(9)/l and 1 x 10(9)/l with or without G-CSF were 12 days (range 8-21), 13 days (10-32) (P = 0.04) and 13 days (9-21), 15 days (11-44) (P = 0.02), respectively. Median times to reach a platelet count of >20 x 10(9)/l with and without G-CSF were 11 days (0-20) and 13 days (9-26), respectively (P = 0.03). The incidence of febrile episodes was significantly lower with G-CSF, 75% vs 100% (P = 0.008). Patients receiving G-CSF had less grade III-IV mucositis than those who did not receive G-CSF (P = 0.01). There was also no increase in the incidence and severity of acute GVHD in patients using G-CSF (P = 0.22). Although the number of relapsing patients was greater in the G-CSF group (seven vs three patients), this was not statistically significant (P = 0.24). Disease-free and overall survival rates did not differ between the two groups (P = 0.58 and 0.53, respectively). The administration of G-CSF after allogeneic PBSC transplantation provided faster neutrophil and platelet engraftment associated with less severe mucositis and less febrile episodes.
机译:我们研究了异基因外周血干细胞(PBSC)移植患者中重组人粒细胞集落刺激因子(G-CSF)对造血恢复和临床结局的影响。 1995年至1998年间接受异体PBSC移植的56例血液系统恶性肿瘤患者进入了这项研究。从异基因PBSC移植后第+1天起,每天接受G-CSF的28例患者,直到连续3天中性粒细胞绝对计数(ANC)达到> 0.5 x 10(9)/ l,然后与28例(对照组)进行比较没有以非随机方式收到G-CSF。研究组和对照组在基线患者和移植特征方面具有可比性。有或没有G-CSF的ANC的中位数时间> 0.5 x 10(9)/ l和1 x 10(9)/ l为12天(8-21),13天(10-32)(P = 0.04 )和13天(9-21),15天(11-44)(P = 0.02)。在有和没有G-CSF的情况下达到血小板计数> 20 x 10(9)/ l的中位时间分别为11天(0-20)和13天(9-26)(P = 0.03)。 G-CSF引起的发热事件发生率显着降低,分别为75%和100%(P = 0.008)。与未接受G-CSF的患者相比,接受G-CSF的患者的III-IV级粘膜炎较少(P = 0.01)。使用G-CSF的患者中,急性GVHD的发生率和严重程度也没有增加(P = 0.22)。尽管G-CSF组复发患者的数量较多(七名患者与三名患者),但在统计学上无统计学意义(P = 0.24)。两组的无病生存率和总生存率无差异(分别为P = 0.58和0.53)。同种异体PBSC移植后G-CSF的给药提供了更快的嗜中性粒细胞和血小板移植,从而减轻了严重的粘膜炎和发热。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号